Citations

Clear

5 citation(s) found for "Shao, Haipeng".

Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study
Yasin, Irfan , Stengel, Anna , Shao, Haipeng , Kaur, Amandeep , Patwardhan, Pranav Pramod , Bailey, Nathanael G. , Inamdar, Kedar , Patel, Anand , Pandiri, M, Sojitra, Payal , Tariq, Hamza , Pan, Zenggang , Wiredja, Danica , Tjota, Melissa Y. , Segal, Jeremy , Chang, Hong , Sallman, David A. , Tefferi, Ayalew , Badar, Talha , Perry, Anamarija M. , Haferlach, Claudia, Patwardhan, Pranav P , Tefferi, Ayalew , Badar, Talha , Venkataraman, Girish , Patel, Anand , Shao, Haipeng, Mason, Emily F. , Ghosh, Sharmila , Zhang, Jingjing , Wang, Peng , Arber, Daniel A. , Haferlach, Claudia , Lager, Angela M.

Mayo Clinic

Cancer | December 19, 2025 | Volume: 132 | Issue: 1 | Pages: No page available

10.1002/cncr.70210 | PMID 41417597 Get It

ABSTRACT Background Isolated chromosome 5/5q losses (–5/5q) without TP53 mutations are associated with favorable outcomes in myeloid neoplasms (MN) with <5% blasts. However, the clinical implication of concurrent −5/5q and TP53 aberrations in MN with ≥5% blasts is poorly understood. Methods Patients with TP53 ‐mutated MN carrying ≥5% blasts assessing the prognostic impact of ‐5/5q on 24‐month overall survival (OS24) were examined. Results Of 587 patients, 515 (88%) exhibited −5/5q overwhelmingly in the context of a complex karyotype (98.3% vs. 61.1% complex karyotype without −5/5q; p < .0001) and multihit TP53 allelic state (88.3% vs. 56.9%; p < .0001). Proportions of patients with blasts ≥20% were comparable between groups with and without −5/5q; p = 0.26. Notably, patients with −5/5q exhibited significantly fewer coalterations; p < .0001. Looking at outcomes, presence of −5/5q was associated with shorter median 24‐month overall survival (7.8 months vs. 11.2 months; p Log‐rank = .012), an effect restricted to subgroups with blasts <20% ( p = .039; N = 163), absent −7/7q ( p = .007; N = 225), or WHO5‐defined single hit allelic state ( p = 0.030; N = 91). Importantly, −5/5q retained independent adverse prognostic significance regardless of TP53 allelic state in a multivariable model. Furthermore, among the subset of 75 (13%) patients undergoing allogeneic stem cell transplantation, −5/5q predicted significantly shorter median 5‐year posttransplant survival (16.2 months vs. median not reached; p Log‐rank = .009). Conclusions These findings emphasize the independent prognostic relevance of chromosome 5/5q losses underscoring the clinical relevance of cytogenetic testing for −5/5q even in this high‐risk cohort.
Karyotypic clonal fraction predicts adverse outcome in TP53 -mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study
Pandiri, M, Stengel, Anna , Shao, Haipeng , Velmurugan, S. , Jacob, Anisha, Symes, Emily , Kaur, Amandeep , Rojek, Alexandra E. , Sojitra, Payal , Wiredja, Danica , Chang, Hong , Patil, Esha, Patel, Jay , Patel, Ami B. , Pan, Zenggang , Findley, Anthony, Badar, Talha , Tariq, Hamza , Sallman, David A. , Bell, Robert , Perry, Anamarija M. , Fitzpatrick, Carrie , Pandiri, Madhavi , Zhou, Qianghua , Venkataraman, Girish , Badar, Talha , Rojek, Alexandra E , Zhang, Jingjing , Wang, Peng , Shao, Haipeng, Jacob, Anisha, Menon, Madhu P , Ghosh, Sharmila , Wool, Geoffrey D. , Arber, Daniel A. , Findley, Anthony, Haferlach, Claudia

Mayo Clinic

Journal of Clinical Pathology | June 26, 2025 | Volume: 78 | Issue: 9 | Pages: 629-635

10.1136/jcp-2024-209954 | PMID 40571403 Get It

We investigated the prognostic impact of blast counts, TP53 allelic state determinants (number of hits, del(17p), variant allele frequency, complex karyotype),and a novel karyotypic clonal cell fraction (≤50% clonal cells vs >50% clonal cells (termed ‘CK50’)) in 495 individuals with TP53- mutated ( TP53 MUT ) myeloid neoplasms. Outcome examined was 24-month survival (OS24). The cohort (median age 71) included 29% (144/495) myelodysplastic syndromes (MDS)/MDS-acute myeloid leukaemia (AML) (1%–19% blasts) and 71% (351/495) AML (≥20% blasts), with 18% (81/460) having low CK50. Overall, 83% received front-line hypomethylating agents. Higher blast counts (<20% vs ≥20%) were marginally associated with CK50 (p=0.08). In the OS24 analysis, blast count showed a marginal association with OS24 (HR 1.3 (95% CI 1.0 to 1.6); p=0.07), while CK50 predicted significantly inferior outcomes (HR=1.7 (95% CI 1.2 to 2.3); p=0.002). In a multivariable model including all TP53 allelic state determinants, only CK50 and complex karyotype remained relevant for predicting adverse outcomes.
Naïve/memory T‐cell phenotypes in leukemic cutaneous T‐cell lymphoma: Putative cell of origin overlaps disease classification
Sokol, Lubomir , Shao, Haipeng , Horna, Pedro , Shao, Haipeng , Moscinski, Lynn C. , Sokol, Lubomir

Mayo Clinic

Cytometry Part B: Clinical Cytometry | October 17, 2018 | Volume: 96 | Issue: 3 | Pages: 234-241

10.1002/cyto.b.21738 | PMID 30328260 Get It

BackgroundMycosis fungoides (MF) and Sézary Syndrome (SS) are clinically distinct cutaneous T‐cell lymphomas with strikingly similar morphologic and phenotypic features. Prior studies have suggested phenotypic differences based on markers of antigen experience, suggesting a different cell of origin.MethodsSeventy‐nine involved peripheral blood or bone marrow samples from 33 patients with SS and 19 patients with MF were studied by 10‐color flow cytometry, including CD62L, CD45RA, CCR4, and PD‐1. Gated tumor events were classified as naïve (TN), central memory (TCM), effector memory (TEM), or effector memory with reacquired CD45RA (TEMRA); based on CD62L+/CD45RA+, CD62L+/CD45RA−, CD62L−/CD45RA−, or CD62L−/CD45RA+ phenotype, respectively. Sequential specimens were compared to assess for phenotypic stability.ResultsThe naïve/memory phenotype of the neoplastic T‐cells was markedly heterogeneous, with a dominant TN, TCM, TEM, or TEMRA subset on 11 (14%), 32 (41%), 30 (38%), and 6 (8%) cases, respectively. There was no correlation between the diagnosis of MF or SS and putative cell of origin (P = 0.4). Overexpression of CCR4 and PD1 was observed in most cases, with higher intensity in SS compared to MF. The naïve/memory phenotype remained the same for 10 patients up to 273 days after the initial analysis; while on six patients, the naïve/memory phenotype was different from the original phenotype.ConclusionsBoth SS and MF can have phenotypic features of any of the major naïve/memory T‐cell subsets, which questions the current principle of “cell‐of‐origin” distinction between SS and MF. Phenotypic shifts within these subsets are common, suggesting a functional state rather than a cell‐of‐origin surrogate. © 2018 International Clinical Cytometry Society
Transformation of T-Cell Acute Lymphoblastic Lymphoma to Peripheral T-Cell Lymphoma: A Report of Two Cases
Markow, Michael J., Mirza, Abu‐Sayeef , Perez, Lia, Shao, Haipeng , Anasetti, Claudio , Sokol, Lubomir , Hussaini, Mohammad , Horna, Pedro , Sokol, Lubomir

Mayo Clinic

Case Reports in Hematology | February 28, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-11

10.1155/2018/9191582 | PMID 29682368 Get It

Nonhepatosplenic/noncutaneous γδ peripheral T-cell lymphoma (NHNCγδ PTCL) represents a miscellaneous group of unrelated T-cell lymphomas of which only isolated cases have been reported. We describe two cases of transformation from T-lymphoblastic leukemia/lymphoma to NHNCγδ PTCL. Transformation into more aggressive disease is a rare event in T-cell lineage-derived hematologic malignancies compared to B-cell neoplasms. Nevertheless, both of our cases involved relapse as PTCL manifested with skin involvement and an overt shift from blastic morphology to large granular leukemia-like mature T cells. Among other notable molecular characteristics, expression of immature markers such as TdT was lost in both cases. Based on cytogenetics, phenotype, and morphology, both patients represent a novel phenomenon of clonal transformation from T-ALL to PTCL which has rarely been reported in the literature. Such transformation may carry important diagnostic and biological implications.
Indeterminate dendritic cell neoplasm of the skin: A 2‐case report and review of the literature
Horna, Pedro , Shao, Haipeng , Idrees, Afshan, Glass, L. Frank, Torres‐Cabala, Carlos A. , Torres-Cabala, Carlos , Horna, Pedro

Mayo Clinic

Journal of Cutaneous Pathology | September 7, 2017 | Volume: 44 | Issue: 11 | Pages: 958-963

10.1111/cup.13017 | PMID 28880462 Get It

Indeterminate dendritic cell neoplasm (IDCN) is an exceedingly rare and mostly cutaneous histiocytosis, frequently associated with other hematopoietic malignancies. We report 2 cases of multilesional cutaneous IDCN. A 55‐year‐old male with no associated malignancy and complete response to ultraviolet phototherapy; and a 72‐year‐old male with chronic myelomonocytic leukemia (CMML). Both cases showed histiocytoid cytology, positivity for CD1a and no expression of langerin or BRAFV600E. With our patients, the literature describes 79 cases of IDCNs, including 65 (82%) with only skin involvement, 7 cases (9%) with involvement of skin and a second site, 5 cases (6%) involving lymph nodes only, 1 splenic lesion and 1 systemic disease. Seventeen cases (22%) were associated with other hematopoietic malignancies, most commonly CMML (6 cases), follicular lymphoma (4 cases) and acute myeloid leukemia (3 cases). All IDCNs associated with myeloid malignancies were limited to the skin, while most cases associated with lymphoma were limited to lymph nodes. Reported responses of cutaneous lesions to ultraviolet phototherapy are encouraging, while systemic chemotherapy is appropriate for clinically aggressive cases and treatment of associated malignancies. Recognition of the clinico‐morphologic spectrum of IDCNs should prevent misdiagnoses and prompt investigation of possible associated neoplasms.